[en] Purpose of review Several entities have been investigated carefully for the symptomatic and structural management of osteoarthritis. This review reports recent findings suggesting that such compounds may delay the structural progression of osteoarthritis. Recent findings The most compelling evidence of a potential for inhibiting the structural progression of osteoarthritis has been obtained with glucosamine sulfate, whereas preliminary results obtained in patients with osteoarthritis of the hands also suggest that chondroitin sulfate could be used in the same indication. At any rate, these two compounds have clearly demonstrated a symptomatic action, mainly in osteoarthritis of the lower limbs. Patients with the less severe radiographic osteoarthritis will experience, in the long run, the most dramatic disease progression in terms of joint space narrowing. Such patients may be particularly responsive to structure-modifying drugs. Summary Glucosamine sulfate has demonstrated its ability to reduce the progression of osteoarthritis in the lower limbs. The preliminary results obtained in the hands suggest that chondroitin sulfate could also be of interest in this indication. An important issue is that all the conclusive studies with such chemical entities resulted from the use of prescription medicines, not over-the-counter pills or food supplements.
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Reginster JY. The prevalence and burden of arthritis. Rheumatology 2002; 41:3-6.
Points to Consider on Clinical Investigation of Medicinal Products Used in the Treatment Of osteoarthritis. CPMP/EWP/784/97. July 1998.
Guidance for Industry-Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis. FDA document 07/1999.
Dougados M, Devogelaer JP, Annefeldt M, et al.: Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis 1996, 55:552-557.
Hardingham TE, Fosang AJ: Proteoglycans. Many forms, many functions. FASEB J 1992, 6:861-870.
Hardingham TE, Bayliss MT: Proteoglycans of articular cartilage: changes in ageing and in joint disease. Semin Arthritis Rheum 1991, 20:12-33.
Bassleer CT, Comban JPA, Bougaret S, et al.: Effects of chondroitin sulfate and interleukin-1β on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage 1998, 6:196-204.
Uebelhart D, Eugene JM, Thonar A, et al.: Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage 1998, 6:6-13.
Nerucci F, Fioravanti A, Cicero MR, et al.: Effects of chondroitin sulfate and interleukin-1β on human chondrocyte cultures exposed to pressurization: a biochemical and morphological study. Osteoarthritis Cartilage 2000, 8:279-287.
Verbruggen G, Veys EM: Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. Arthritis Rheum 1996, 39:308-320.
Verbruggen G, Goemaere S, Veys EM: Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002, 21:231-243. This study presents the clinical validation of a new scoring system for finger joint OA, demonstrating that CS can reduce the individual patient's risk for developing erosive OA.
Rovetta G, Monteforte P, Molfetta G, et al.: Chondroitin sulfate in erosive osteoarthritis of the hands. Int J Tissue React 2002, 24:29-32.
Setnikar I, Cereda R, Pacine MA, et al.: Antireactive properties of glucosamine sulfate. Arzneim Forsch/Drug Res 1991, 41:157-161.
Jimenez SA, Dodge GR. The effects of glucosamine sulfate (GSO 4) on human chondrocyte gene expression. Osteoarthritis Cartilage 1997, 5S:72 (abstract).
Dodge GR, Hawkins JF, Jimenez SA: Modulation of aggrecan, MMP1 and MMP3 productions by glucosamine sulfate in cultured human osteoarthritis articular chondrocytes. Arthritis Rheum 1999, 42S:253.
Basleer C, Rovati L, Franchimont P: Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritis articular cartilage in vitro. Osteoarthritis Cartilage 1998, 6:427-434.
Sandy JD, Gamett D, Thompson V, et al.: Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998, 355:59-66.
Shikhman A, Alaaeddine N, Lotz La Jolla MK: N-acetylglucosamine prevents IL-1 mediated activation of chondrocytes. Arthritis Rheum 1991, 42S:381.
Abelda SM, Buck CA: Integrins and other cell adhesion molecules. FASEB J 1990, 4:2868-2880.
Piperno M, Reboul P, Hellio Le Graverand MP, et al.: Glucosamine sulfate modulates dysregulated activities of human osteoarthritis chondrocytes in vitro. Osteoarthritis Cartilage 2000, 8:207-212.
Conrozier T, Mathieu P, Piperno M, et al.: Glucosamine sulfate significantly reduced cartilage destruction in a rabbit model of osteoarthritis. Arthritis Rheum 1998, 41S:147.
Reginster JY, Deroisy R, Rovati LC, et al.: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
Pavelka K, Gatterova J, Olejarova M, et al.: Glucosamine sulfate use and delay of progression of knee osteoarthritis. Arch Intern Med 2002, 162:2113-2123. This is another well-designed prospective, placebo-controlled trial confirming that GS can modify the progression of joint structure and symptom changes in knee OA.
Bruyere O, Honore A, Rovati LC, et al.: Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scand J Rheumatol 2002, 31:13-16.
Bruyere O, Honore A, Etghen O, et al.: Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis Cartilage 2003, 11:1-5. This interesting post hoc analysis suggests that patients with the less severe radiographic OA may be particularly responsive to structure-modifying drugs.
Tapadinhas MJ, Rivera IC, Bignamini AA: Oral glucosamine sulphate in the management of arthrosis; report on a multi-centre open investigation in Portugal. Pharmacotherapeutica 1982, 3:157-168.
Adams ME: Hype about glucosamine. Lancet 1999, 354:353-354.
Rovati LC, Annefeld M, Giacovelli G, et al.: Glucosamine in osteoarthritis. Lancet 1999, 354:1640.
Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002, 29:2407-2409.